A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
Clinical trial NCT05503355 · UNKNOWN
Trial details
- NCT number
- NCT05503355
- Sponsor
- BioSight Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-17
- Primary completion
- 2025-08-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.